Skip to main content

Table 1 Clinical descriptions for cross-sectional HIV patients

From: Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4+ T cell recovery after the initiation of antiretroviral therapy for HIV disease

Patients N VL (copies/mL)# CD4 (cells/ul)# Mean age# Male%
HIV Viral Controllersa 31 75 (75–184.3) 710 (514–945.5) 45.5 (43–52.7) 64.5%
HIV Viremicb 34 89246 (45295.5–174381) 304 (202.2–451) 43 (39.2–47.7) 79.4%
ART-suppressedc 34 75 (50–75) 388.5 (313.5–500.2) 47 (41.7–50) 79.4%
Seronegative 30 NA NA 42 (37.2–45.7) 100.0%
  1. aHIV viral controllers were defined as untreated subjects with at least three plasma HIV VL < 1,000 copies/mL during a 12 month period.
  2. bHIV viremics were defined as untreated individuals with VL > 10,000 copies/ml.
  3. cART-suppressed subjects had VL < 75 copies/mL for a period between 2–4 years after treatment initiation, with only one viral blip >1000 copies/mL permissible during the analysis time.
  4. #Values are expressed as median ± interquartile range.